Top 5 Vendors in the Global Laryngeal Cancer Therapeutics Market 2019-2023 | Technavio

LONDON--(BUSINESS WIRE)-- The increase in smoking and the consumption of tobacco products have resulted in increased incidences of laryngeal cancer. These factors coupled with the high mortality rate have led to the growing demand for therapeutics such as chemotherapy and targeted therapy for laryngeal cancer treatment. Because of factors such as the advent of novel therapies, the laryngeal cancer therapeutics market is expected to grow during the forecast period. This industry research report also presents a competitive analysis of the market by type (biologics and small molecules) and geography (Asia, Europe, North America, and ROW).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190704005178/en/

Technavio has published a new market research report on the global laryngeal cancer therapeutics market from 2019-2023. (Graphic: Business Wire)

Competitive vendor landscape

The global laryngeal cancer therapeutics market is highly competitive with major vendors such as Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., and Sanofi competing on the basis of price, quality, product/service offerings, and market presence.

“To gain higher market shares, companies as a key strategy are involved in acquisitions and partnerships along with effective product launches. Leading corporations are aggressively pursuing to enhance their capabilities to gain a competitive edge through joint ventures, MoUs, and agreements or acquisitions,” says a senior analyst at Technavio.

Top five laryngeal cancer therapeutics vendors

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company develops, manufactures, and sells biopharmaceutical products worldwide. The company operates its operations through the biopharmaceuticals segment. This segment is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative medicines that help patients prevail over serious diseases. Its offerings include OPDIVO, YERVOY, PLATINOL, TAXOL, PARAPLATIN, and HYDREA.

Eli Lilly and Co.

Eli Lilly and Company develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, human pharmaceutical products and animal health products. Its offerings include ERBITUX and GEMZAR.

F. Hoffmann-La Roche Ltd.

The company provides in-vitro diagnostics and drugs for cancer and transplantation and specializes in medicines for chronic diseases, infectious diseases, and microbiology. The company operates in two segments, Pharmaceuticals and Diagnostics. The company’s offerings include XELODA, TECENTRIQ, and AVASTIN.

Merck & Co. Inc.

Merck & Co., Inc. provides healthcare solutions worldwide. The company operates through three segments, pharmaceutical, animal health, and others. Its offerings include KEYTRUDA, which is a PD-1 inhibitor approved for the treatment of various head and neck cancer indications, including laryngeal cancer.

Sanofi

Sanofi provides therapeutic solutions worldwide. The company operates through three segments, pharmaceuticals, consumer healthcare, and vaccines. Its offerings include TAXOTERE, which is chemotherapy approved for the treatment of laryngeal cancer.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Browse Related Reports:

• Global Japanese Encephalitis Vaccines Market 2019-2023 - The market research study identifies Bharat Biotech Ltd., Biological E. Ltd., Green Cross Corp., Sanofi, Valneva SE. as the leading players in the global Japanese encephalitis vaccines market.
• Global Obsessive-Compulsive Disorder Drugs Market 2019-2023 - The market research study identifies Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, Novartis AG, and Pfizer Inc. as the leading players in the global obsessive-compulsive disorder drugs market.

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190704005178/en/